{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=IL-12+DNA",
    "query": {
      "intervention": "IL-12 DNA"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 34,
    "total_pages": 4,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=IL-12+DNA&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-09T02:05:41.004Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02143518",
      "title": "Safety and Immunogenicity Study of Na-GST-1 With or Without CpG",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Hookworm Infection",
        "Hookworm Disease"
      ],
      "interventions": [
        {
          "name": "Na-GST-1/Alhydrogel®",
          "type": "BIOLOGICAL"
        },
        {
          "name": "CpG 10104",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Baylor College of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 24,
      "start_date": "2014-10",
      "completion_date": "2016-10",
      "has_results": true,
      "last_update_posted_date": "2025-07-04",
      "last_synced_at": "2026-09-09T02:05:41.004Z",
      "location_count": 1,
      "location_summary": "Washington D.C., District of Columbia",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02143518"
    },
    {
      "nct_id": "NCT00195312",
      "title": "Study Evaluating Vaccine in Adults With HIV",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "HIV-1 gag DNA (formulated with bupivacaine)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "IL-15 DNA (formulated with bupivacaine)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "IL-12 DNA (formulated with bupivacaine)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Sodium chloride injection USP (0.9%)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Wyeth is now a wholly owned subsidiary of Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 91,
      "start_date": "2005-08",
      "completion_date": "2007-08",
      "has_results": false,
      "last_update_posted_date": "2007-12-05",
      "last_synced_at": "2026-09-09T02:05:41.004Z",
      "location_count": 6,
      "location_summary": "Birmingham, Alabama • Denver, Colorado • Orlando, Florida + 3 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00195312"
    },
    {
      "nct_id": "NCT03491683",
      "title": "INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Glioblastoma"
      ],
      "interventions": [
        {
          "name": "INO-5401",
          "type": "BIOLOGICAL"
        },
        {
          "name": "INO-9012",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Cemiplimab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Radiation Therapy",
          "type": "RADIATION"
        },
        {
          "name": "Temozolomide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "RADIATION",
        "DRUG"
      ],
      "sponsor": "Inovio Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 52,
      "start_date": "2018-05-31",
      "completion_date": "2026-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-05-04",
      "last_synced_at": "2026-09-09T02:05:41.004Z",
      "location_count": 21,
      "location_summary": "Duarte, California • Palo Alto, California • San Francisco, California + 15 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03491683"
    },
    {
      "nct_id": "NCT01578889",
      "title": "Evaluating the Safety of and Immune Response to HIV-MAG DNA Vaccine With or Without Plasmid IL-12 Adjuvant Delivered Intramuscularly Via Electroporation Followed by VSV-gag HIV Vaccine Boost in Healthy, HIV-Uninfected Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "HIV-MAG vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "IL-12 pDNA adjuvant",
          "type": "BIOLOGICAL"
        },
        {
          "name": "VSV HIV gag vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Ichor Medical Systems TriGrid™ Delivery System (TDS) electroporation (EP) device",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DEVICE"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 100,
      "start_date": "2012-05",
      "completion_date": "2016-10",
      "has_results": false,
      "last_update_posted_date": "2021-10-15",
      "last_synced_at": "2026-09-09T02:05:41.004Z",
      "location_count": 5,
      "location_summary": "New York, New York • Rochester, New York • Philadelphia, Pennsylvania + 1 more",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Rochester",
          "state": "New York"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01578889"
    },
    {
      "nct_id": "NCT03823131",
      "title": "Optimizing Antitumor Immunity Using Plasmid Electroporation, Pembrolizumab, and Epacadostat",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Head and Neck Squamous Cell Carcinoma",
        "Recurrent Head and Neck Squamous Cell Carcinoma",
        "Unresectable Head and Neck Squamous Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "ImmunoPulse",
          "type": "DEVICE"
        },
        {
          "name": "Epacadostat",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "CORVax",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Tavokinogene telseplasmid",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Chase Heaton, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 14,
      "start_date": "2019-05-02",
      "completion_date": "2022-07-31",
      "has_results": true,
      "last_update_posted_date": "2023-05-09",
      "last_synced_at": "2026-09-09T02:05:41.004Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03823131"
    },
    {
      "nct_id": "NCT04357821",
      "title": "Combinatorial Therapy to Induce an HIV Remission",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "HIV/AIDS"
      ],
      "interventions": [
        {
          "name": "Combination Intervention",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, San Francisco",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "67 Years",
        "sex": "ALL",
        "summary": "18 Years to 67 Years"
      },
      "enrollment_count": 11,
      "start_date": "2020-08-01",
      "completion_date": "2025-06-12",
      "has_results": true,
      "last_update_posted_date": "2026-08-28",
      "last_synced_at": "2026-09-09T02:05:41.004Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04357821"
    },
    {
      "nct_id": "NCT01502293",
      "title": "Trial of pIL-12 Electroporation Malignant Melanoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Melanoma"
      ],
      "interventions": [
        {
          "name": "Tavokinogene Telseplasmid (tavo)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "OncoSec Medical System (OMS)",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DEVICE"
      ],
      "sponsor": "OncoSec Medical Incorporated",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 51,
      "start_date": "2012-02-14",
      "completion_date": "2016-03-21",
      "has_results": true,
      "last_update_posted_date": "2023-05-15",
      "last_synced_at": "2026-09-09T02:05:41.004Z",
      "location_count": 6,
      "location_summary": "San Francisco, California • Santa Monica, California • Denver, Colorado + 3 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Lakeland",
          "state": "Florida"
        },
        {
          "city": "Bethlehem",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01502293"
    },
    {
      "nct_id": "NCT02345330",
      "title": "Trial of pIL-12 Electroporation in Squamous Cell Carcinoma of the Head and Neck (IL12HNSCC)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Head and Neck Squamous Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "Tavokinogene Telseplasmid (tavo)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "OncoSec Medical System (OMS)",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DEVICE"
      ],
      "sponsor": "OncoSec Medical Incorporated",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 4,
      "start_date": "2015-05-21",
      "completion_date": "2016-11-14",
      "has_results": true,
      "last_update_posted_date": "2023-05-15",
      "last_synced_at": "2026-09-09T02:05:41.004Z",
      "location_count": 2,
      "location_summary": "San Francisco, California • Chicago, Illinois",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02345330"
    },
    {
      "nct_id": "NCT07722741",
      "title": "Personalized Neoantigen Vaccine Plus IL-12 (INO-9012) Versus Active Surveillance in Subjects With High-Risk HCC",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "HCC"
      ],
      "interventions": [
        {
          "name": "GNOS-PV02 + INO-9012 delivered by intradermal injection, followed by electroporation",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Electroporation Device",
          "type": "DEVICE"
        },
        {
          "name": "INO-9012",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DEVICE"
      ],
      "sponsor": "Geneos Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 90,
      "start_date": "2026-09",
      "completion_date": "2032-06",
      "has_results": false,
      "last_update_posted_date": "2026-09-04",
      "last_synced_at": "2026-09-09T02:05:41.004Z",
      "location_count": 7,
      "location_summary": "Atlanta, Georgia • New Orleans, Louisiana • Baltimore, Maryland + 4 more",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "New Orleans",
          "state": "Louisiana"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07722741"
    },
    {
      "nct_id": "NCT00111605",
      "title": "Study of an HIV Preventive Vaccine Given With or Without an Adjuvant in HIV Uninfected Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "HIV-1 gag DNA",
          "type": "BIOLOGICAL"
        },
        {
          "name": "HIV-1 gag DNA plus IL-12 DNA adjuvant",
          "type": "BIOLOGICAL"
        },
        {
          "name": "CTL MEP/RC529-SE/GM-CSF (CTL MEP vaccine)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Sodium chloride injection (0.9%)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 144,
      "start_date": null,
      "completion_date": "2008-05",
      "has_results": false,
      "last_update_posted_date": "2021-10-14",
      "last_synced_at": "2026-09-09T02:05:41.004Z",
      "location_count": 3,
      "location_summary": "Birmingham, Alabama • Baltimore, Maryland • Nashville, Tennessee",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00111605"
    }
  ]
}